News

Spyryx Presents Data Ably Supporting SPX-101 as Potential Treatment for All CF Patients

Spyryx Biosciences recently presented preclinical data supporting the clinical benefits of its cystic fibrosis (CF) treatment candidate SPX-101, intended to improve lung function in all patients regardless of their underlying disease-causing mutation. The data, presented in four posters at the recent North American Cystic Fibrosis Conference (NACFC) in Indianapolis,…

FDA Acts to Advance Potential Inhaled Treatment of Resistant Bacteria Tied to Lung Infections

BIOC51, a potential nitric oxide-based treatment of chronic pulmonary infections due to Pseudomonas aeruginosa bacteria in patients with cystic fibrosis (CF),was awarded special status to promote and speed its development, Novoclem Therapeutics announced. BIOC51 was granted what is known as Qualified Infectious Disease Product (QIDP) status by the U.S. Food and Drug Administration (FDA), whose incentives include priority review…

#NACFC2017 – Latest Trial Data on Vertex CF Therapies and New Combos Show Benefits

Vertex Pharmaceuticals recently presented data from several clinical trials of cystic fibrosis treatments showing positive outcomes for CF patients. Data focused on the approved therapies Orkambi and Kalydeco, and investigative treatments like tezacaftor/ivacaftor and several triple regimens. These findings were presented at the North American Cystic Fibrosis Conference (NACFC) that ran Nov.

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.